Helsinn, a Swiss pharmaceutical group focused on building quality cancer care announces a collaboration with Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease.
The collaboration will focus on recognizing patient entrepreneurs who are developing innovative ideas and concepts for better management of cancer using pharmaceuticals, biotechnology, medical devices and nutritional supplements. Linking entrepreneurs with senior team and board members from Helsinn and Lyfebulb will spotlight the entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration.

Read more